Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Borgo in connection with its inaugural issuance of primary capital instruments (AT1)
Mandate

Vinge advises Borgo in connection with its inaugural issuance of primary capital instruments (AT1)

January 29, 2026 Banking and Finance

Vinge has advised Borgo AB (publ) in connection with its successful issuance of primary capital instruments (so called “AT1 bonds”) in the amount of SEK 350 million with a floating rate coupon of 3-month STIBOR + 390 basis points.

The AT1 bonds are perpetual with a first call option after five years, and they are intended to be admitted to trading on Nasdaq Stockholm. SEB acted as sole manager in connection with the bond issuance.
 
Borgo is a Swedish mortgage institution (Credit Market Company) which is under the supervision of the Swedish FSA. Borgo offers mortgages to the prime segment in Sweden as well as savings accounts. Mortgages are distributed by ICA Banken, Ikano, Söderberg & Partners, Sparbanken Syd, Lån & Spar Bank and Ålandsbanken. As a modern, highly digitalised player, Borgo aims to offer better mortgage terms to more people in an efficient, transparent and sustainable way. 
 
Vinge’s team consisted of Mikael Ståhl, Lionardo Ojeda, Caroline Krassén, August Ahlin and Nilufer Nouri.

Related

Vinge advises Sobro on its investment in Västkustens Konstruktionsbyrå

 Västkustens Konstruktionsbyrå has decided to broaden its ownership structure by bringing in Sobro as a new co-partner and majority shareholder. The founders will remain with the company as the CEO and CTO respectively, and as significant shareholders. Västkustens Konstruktionsbyrå is an engineering consultancy company based in Gothenburg with cutting-edge expertise in project management, civil engineering and design.
April 23, 2026

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

 Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026